Tempest Therapeutics, Inc.
NASDAQ: TPST0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Matthew Angel
- Employees
- 24
- Headquarters
- Brisbane, United States
- IPO year
- 2012
- Market cap
- $5.2M
- Website
- https://www.tempesttx.com
Loading TPST…
Loading profile data…Frequently asked questions about TPST
What does Tempest Therapeutics, Inc. (TPST) do?
Tempest Therapeutics Inc. is an oncology company, currently in the clinical development phase, dedicated to advancing novel small molecule drugs designed to combat cancer. The firm's pipeline highlights two key therapeutic candidates: TPST-1495, a compound functioning as a dual inhibitor of EP2 and EP4 receptors (which are implicated in prostagl...
Where does TPST trade?
Tempest Therapeutics, Inc. (TPST) trades on the NASDAQ Capital Market.
What sector is TPST in?
Tempest Therapeutics, Inc. (TPST) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Tempest Therapeutics, Inc.?
Matthew Angel is the chief executive officer of Tempest Therapeutics, Inc. (TPST).
Where is Tempest Therapeutics, Inc. headquartered?
Tempest Therapeutics, Inc. is headquartered in United States.
Does TPST pay a dividend?
Tempest Therapeutics, Inc. (TPST) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did TPST go public?
Tempest Therapeutics, Inc. (TPST) completed its initial public offering in 2012.